Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
21-Apr-2025 | 4,960 | 5,008 | 4,921 | 5,000.4 | 23,958 | 48,69,72,954.9 | 53,761 |
22-Apr-2025 | 5,010 | 5,075 | 4,988.7 | 5,013.6 | 8,974 | 21,69,75,458.1 | 11,751 |
23-Apr-2025 | 5,064.9 | 5,250.5 | 5,020 | 5,233 | 26,320 | 84,21,62,426 | 52,647 |
24-Apr-2025 | 5,268 | 5,299 | 5,165.5 | 5,201.2 | 22,413 | 71,98,86,844.9 | 57,162 |
25-Apr-2025 | 5,238 | 5,238 | 4,990 | 5,033.5 | 15,193 | 39,53,31,983.9 | 24,957 |
28-Apr-2025 | 4,999 | 5,088 | 4,995 | 5,025.8 | 12,452 | 25,97,58,026.4 | 23,296 |
29-Apr-2025 | 5,028.1 | 5,047.3 | 4,960.7 | 5,030.8 | 9,563 | 26,57,44,150.1 | 16,070 |
30-Apr-2025 | 5,041 | 5,165.9 | 5,041 | 5,116 | 20,753 | 58,67,05,538 | 47,959 |
02-May-2025 | 5,120 | 5,139.5 | 5,053 | 5,076 | 13,237 | 27,69,29,831.5 | 25,466 |
05-May-2025 | 5,050 | 5,150 | 5,041 | 5,085.5 | 10,027 | 15,18,77,049.5 | 10,269 |
06-May-2025 | 5,061 | 5,095.5 | 5,001 | 5,023.5 | 11,710 | 16,88,72,300.5 | 14,131 |
07-May-2025 | 4,978 | 5,055 | 4,975 | 5,033 | 11,638 | 17,93,18,753.5 | 16,047 |
08-May-2025 | 5,025 | 5,033 | 4,920.5 | 4,939.5 | 20,435 | 76,44,85,750 | 1,08,672 |
09-May-2025 | 4,850 | 4,961 | 4,850 | 4,946.5 | 14,449 | 26,02,46,868.5 | 24,127 |
12-May-2025 | 4,969 | 5,065.5 | 4,935 | 5,020.5 | 18,223 | 77,79,59,041 | 48,223 |
13-May-2025 | 5,028.5 | 5,145 | 5,025 | 5,126.5 | 14,383 | 25,75,05,578.5 | 22,291 |
14-May-2025 | 5,147.5 | 5,159.5 | 5,046.5 | 5,127 | 16,788 | 53,23,70,093.5 | 61,885 |
15-May-2025 | 5,163 | 5,320.5 | 5,099 | 5,277 | 26,180 | 61,27,53,038 | 54,846 |
16-May-2025 | 5,300 | 5,316 | 5,200 | 5,221 | 22,074 | 49,03,05,122 | 40,290 |
19-May-2025 | 5,225 | 5,400 | 5,192 | 5,324 | 38,306 | 95,62,71,672.5 | 75,421 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
